The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Cobenfy, set to launch in October, will have a list price that would cost about ... and even the more recent drugs can cause ...
Recommended Reading Psychiatry drugs finally have ... than a dozen antipsychotics for schizophrenia, and many have ...
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...